Effectiveness of Non-invasive Vagal Nerve Stimulation in Parkinson's Disease: A Comprehensive Systematic Review and Meta-analysis
Ahmed Elshahat1, Moaz Abouelmagd2, Obai Yousef3, Ismail Ibrahim4, Ahmed Negida5
1Faculty of Medicine, Al-Azhar University, Cairo, Egypt, 2Faculty of Medicine, Cairo University, Cairo, Egypt, 3Factually of Medicine, Tartous University, 4Faculty of Health Sciences, Fenerbahce University, Istanbul, Turkey, 5Virginia Commonwealth University
Objective:
This systematic review aimed to evaluate the existing evidence on the efficacy of nVNS in managing PD symptoms.
Background:
Parkinson's disease (PD) is a debilitating neurodegenerative disorder characterized by movement impairments. Vagus nerve stimulation (VNS) is a non-invasive brain stimulation technique that has shown promise in treating various neurological conditions, including PD.
Design/Methods:
A comprehensive literature search was conducted to identify relevant studies published up to July 2024. The included studies investigated the effect of nVNS on various PD motor symptoms. The quality of studies was assessed using the Cochrane Risk of Bias 2 (ROB-2) and NIH tool for RCTs, single-arm studies, and case series studies respectively. Statistical analysis was conducted using Review Manager version 5.4.1 with outcomes expressed as Mean differences (MD) with 95% confidence intervals (CI).
Results:
The systematic review included eight randomized controlled trials (RCTs), one single-arm study, and one case series, encompassing a total of 217 patients with PD. The review revealed a potential benefit of nVNS in reducing Freezing of Gait (FOG) in PD, as indicated by a significant improvement in FOG Questionnaire scores (p= 0.04). However, no significant differences were found in UPDRS-III (p= 0.19 and p= 0.89 for on and off-medication conditions, respectively), UPDRS-II (p= 0.9), UPDRS-I (p= 0.46), Time Up and Go (p= 0.61), stand time (p= 0.87), walking speed (p= 0.22), or step length measured in meters (p= 0.8). Interestingly, a significant improvement was observed in step length measured in centimetres (p= 0.0005). No study reported serious adverse effects associated with nVNS treatment.
Conclusions:
Our finding suggests a potential benefit of nVNS in reducing FOG in PD, but did not demonstrate a significant improvement in other motor symptoms. Larger, longer follow-up studies are needed to confirm the effect nVNS on PD management.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.